KEI Briefing Note 2019:1 International Reference Pricing August 22, 2019 International Reference Pricing, often referred to as External Reference Pricing (ERP), is the practice of using a price in a foreign market as a benchmark for an acceptable price in… Continue Reading
As part of the work program of the Standing Committee on the Law of Patents (SCP), the secretariat of the World Intellectual Property Organization (WIPO) has been mandated to prepare a 40-50 page review of “existing research on patents and… Continue Reading
UPDATE: On 29 July 2019, the co-facilitators (Ambassadors of Georgia and Thailand) of the intergovernmental consultations on a UN political declaration on universal health coverage announced that the silence procedure was broken by “several delegations on paragraphs 29, 68, 69,… Continue Reading
On Thursday, 11 July 2019, the 41st session of the Human Rights Council (HRC) adopted, without a vote, resolution A/HRC/41/L.13, “Access to medicines and vaccines in the context of the right of the highest attainable standard of physical and mental… Continue Reading
UPDATE: On 4 July 2019, the Core Group will submit a “TABLING REV 1” version of their resolution on “Access to medicines and vaccines in the context of the right of everyone to the enjoyment of the highest attainable standard… Continue Reading
At the 41st session (24 June 2019 – 12 July 2019) of the Human Rights Council, a bloc of countries known as the the Core Group (Brazil, China, Egypt, Indonesia, India, Senegal, South Africa and Thailand) have circulated a resolution… Continue Reading
On Monday, 24 June 2019, Knowledge Ecology International (KEI) delivered this opening statement at WIPO’s 30th Session of the Standing Committee on the Law of Patents (SCP). The Committee elected a new chair, Sarah Whitehead, United Kingdom of Great Britain… Continue Reading
Zolgensma, Novartis’s new $2.1 million gene therapy for children with spinal muscular atrophy (SMA), is a remarkable breakthrough with a steep price tag: the cost per child is $2.125 million. The treatment was developed using research funded by the National… Continue Reading
June 14, 2019 Zolgensma, the Novartis brand name for the new $2.1 million gene therapy for treatment of Spinal Muscular Atrophy (SMA), appears to be a remarkable medical breakthrough treatment. It is also, like all of the new cell- and… Continue Reading